Cargando…

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

BACKGROUND. The Hermine study observed the use of trastuzumab for metastatic breast cancer (MBC) in routine practice, including patients who received trastuzumab treatment beyond progression (TBP). PATIENTS AND METHODS. The study observed 623 patients for ≥2 years. Treatment was given according to o...

Descripción completa

Detalles Bibliográficos
Autores principales: Extra, Jean-Marc, Antoine, Eric C., Vincent-Salomon, Anne, Delozier, Thierry, Kerbrat, Pierre, Bethune-Volters, Anne, Guastalla, Jean-Paul, Spielmann, Marc, Mauriac, Louis, Misset, Jean-Louis, Serin, Daniel, Campone, Mario, Hebert, Christophe, Remblier, Céline, Bergougnoux, Loïc, Campana, Frank, Namer, Moïse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228018/
https://www.ncbi.nlm.nih.gov/pubmed/20671105
http://dx.doi.org/10.1634/theoncologist.2009-0029
_version_ 1782217798440714240
author Extra, Jean-Marc
Antoine, Eric C.
Vincent-Salomon, Anne
Delozier, Thierry
Kerbrat, Pierre
Bethune-Volters, Anne
Guastalla, Jean-Paul
Spielmann, Marc
Mauriac, Louis
Misset, Jean-Louis
Serin, Daniel
Campone, Mario
Hebert, Christophe
Remblier, Céline
Bergougnoux, Loïc
Campana, Frank
Namer, Moïse
author_facet Extra, Jean-Marc
Antoine, Eric C.
Vincent-Salomon, Anne
Delozier, Thierry
Kerbrat, Pierre
Bethune-Volters, Anne
Guastalla, Jean-Paul
Spielmann, Marc
Mauriac, Louis
Misset, Jean-Louis
Serin, Daniel
Campone, Mario
Hebert, Christophe
Remblier, Céline
Bergougnoux, Loïc
Campana, Frank
Namer, Moïse
author_sort Extra, Jean-Marc
collection PubMed
description BACKGROUND. The Hermine study observed the use of trastuzumab for metastatic breast cancer (MBC) in routine practice, including patients who received trastuzumab treatment beyond progression (TBP). PATIENTS AND METHODS. The study observed 623 patients for ≥2 years. Treatment was given according to oncologists' normal clinical practices. Endpoints included duration of treatment, efficacy, and cardiac safety. The TBP subanalysis compared overall survival (OS) in 177 patients who received first-line trastuzumab and either continued trastuzumab for ≥30 days following progression or stopped at or before progression. RESULTS. The median treatment duration was 13.3 months. In the first-, second-, and third-line or beyond treatment groups, the median time to progression (TTP) were 10.3 months, 9.0 months, and 6.3 months, and the median OS times were 30.3 months, 27.1 months, and 23.2 months, respectively. Heart failure was observed in 2.6% of patients, although no cardiac-associated deaths occurred. In the TBP subanalysis, the median OS duration from treatment initiation and time of disease progression were longer in patients who continued receiving trastuzumab TBP (>27.8 months and 21.3 months, respectively) than in those who stopped (16.8 months and 4.6 months, respectively). However, the groups were not completely comparable, because patients who continued trastuzumab TBP had better prognoses at treatment initiation. The median TTP was longer in patients who continued trastuzumab TBP (10.2 months) than in those who stopped (7.1 months). CONCLUSION. The Hermine findings confirm that the pivotal trials of first-line trastuzumab treatment in MBC patients are applicable in clinical practice. The subanalysis suggests that trastuzumab TBP offers a survival benefit to MBC patients treated with first-line trastuzumab.
format Online
Article
Text
id pubmed-3228018
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-32280182012-04-25 Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study Extra, Jean-Marc Antoine, Eric C. Vincent-Salomon, Anne Delozier, Thierry Kerbrat, Pierre Bethune-Volters, Anne Guastalla, Jean-Paul Spielmann, Marc Mauriac, Louis Misset, Jean-Louis Serin, Daniel Campone, Mario Hebert, Christophe Remblier, Céline Bergougnoux, Loïc Campana, Frank Namer, Moïse Oncologist Academia–Pharma Intersect BACKGROUND. The Hermine study observed the use of trastuzumab for metastatic breast cancer (MBC) in routine practice, including patients who received trastuzumab treatment beyond progression (TBP). PATIENTS AND METHODS. The study observed 623 patients for ≥2 years. Treatment was given according to oncologists' normal clinical practices. Endpoints included duration of treatment, efficacy, and cardiac safety. The TBP subanalysis compared overall survival (OS) in 177 patients who received first-line trastuzumab and either continued trastuzumab for ≥30 days following progression or stopped at or before progression. RESULTS. The median treatment duration was 13.3 months. In the first-, second-, and third-line or beyond treatment groups, the median time to progression (TTP) were 10.3 months, 9.0 months, and 6.3 months, and the median OS times were 30.3 months, 27.1 months, and 23.2 months, respectively. Heart failure was observed in 2.6% of patients, although no cardiac-associated deaths occurred. In the TBP subanalysis, the median OS duration from treatment initiation and time of disease progression were longer in patients who continued receiving trastuzumab TBP (>27.8 months and 21.3 months, respectively) than in those who stopped (16.8 months and 4.6 months, respectively). However, the groups were not completely comparable, because patients who continued trastuzumab TBP had better prognoses at treatment initiation. The median TTP was longer in patients who continued trastuzumab TBP (10.2 months) than in those who stopped (7.1 months). CONCLUSION. The Hermine findings confirm that the pivotal trials of first-line trastuzumab treatment in MBC patients are applicable in clinical practice. The subanalysis suggests that trastuzumab TBP offers a survival benefit to MBC patients treated with first-line trastuzumab. AlphaMed Press 2010-08 2010-07-29 /pmc/articles/PMC3228018/ /pubmed/20671105 http://dx.doi.org/10.1634/theoncologist.2009-0029 Text en ©AlphaMed Press available online without subscription through the open access option.
spellingShingle Academia–Pharma Intersect
Extra, Jean-Marc
Antoine, Eric C.
Vincent-Salomon, Anne
Delozier, Thierry
Kerbrat, Pierre
Bethune-Volters, Anne
Guastalla, Jean-Paul
Spielmann, Marc
Mauriac, Louis
Misset, Jean-Louis
Serin, Daniel
Campone, Mario
Hebert, Christophe
Remblier, Céline
Bergougnoux, Loïc
Campana, Frank
Namer, Moïse
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
title Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
title_full Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
title_fullStr Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
title_full_unstemmed Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
title_short Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
title_sort efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational hermine study
topic Academia–Pharma Intersect
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228018/
https://www.ncbi.nlm.nih.gov/pubmed/20671105
http://dx.doi.org/10.1634/theoncologist.2009-0029
work_keys_str_mv AT extrajeanmarc efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT antoineericc efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT vincentsalomonanne efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT delozierthierry efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT kerbratpierre efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT bethunevoltersanne efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT guastallajeanpaul efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT spielmannmarc efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT mauriaclouis efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT missetjeanlouis efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT serindaniel efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT camponemario efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT hebertchristophe efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT remblierceline efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT bergougnouxloic efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT campanafrank efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy
AT namermoise efficacyoftrastuzumabinroutineclinicalpracticeandafterprogressionformetastaticbreastcancerpatientstheobservationalherminestudy